

Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study



Please scan this with your smartphone to obtain a copy of these materials. Copies of this are for personal use only and may not be reproduced without permission from ENDO and the authors of this poster

Adriana Gabriela Ioachimescu, MD, PhD^{1*}, Richard Joseph Auchus, MD, PhD^{2*}, Wenyu Huang, MD, PhD^{3*}, Joanna L. Spencer-Segal, MD, PhD^{2*}, Kevin Choong Ji Yuen, MD, FRCP (UK), FACE^{4*}, Kelley C Dacus, PharmD^{5*}, William Henry Ludlam, PhD, MD^{6*}, Elizabeth Kay Babler, PhD, APNP^{7*}, Ashis K Das, PhD, MPH, MBBS^{8*}, Cynthia Campos, MPH^{8*}, Michael S Broder, MD, MSHS^{8*}, Maria Fleseriu, MD^{9*}

¹Emory University, Atlanta, GA, USA, ²University of Michigan, Ann Arbor, MI, USA, ³Northwestern University, Chicago, IL, USA, ⁴Barrow Neurological Institute, Scottsdale, AZ, USA, ⁵Recordati Rare Diseases Inc., Metairie, LA, USA, ⁶Recordati Rare Diseases Inc., Mountain Lakes, NJ, USA, ⁷Recordati Rare Diseases Inc., Franklin, WI, USA, ⁸PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USA, ⁹Oregon Health & Science University, Portland, OR, USA
*Potential conflict of interest may exist. Refer to the Meeting App.

Background

- Cushing's disease (CD), the most common form of endogenous Cushing's syndrome (CS), results when a pituitary corticotroph adenoma produces excess adrenocorticotropic hormone (ACTH).
- Medical therapy is indicated when a patient has failed first-line surgery, surgery is not feasible, while awaiting onset of radiation, or when there is recurrent hypercortisolism.
- Osilodrostat is a potent oral inhibitor of 11β- hydroxylase with demonstrated efficacy in normalizing urinary free cortisol (UFC) in Cushing's disease (CD) patients and was well tolerated in clinical trials.
- Information describing osilodrostat's use in clinical practice is limited.
- We present osilodrostat dosing and titration information from a real-world study in U.S. patients with endogenous Cushing's syndrome (CS), focused on CD.

Methods

- ILLUSTRATE, a retrospective chart review study analyzed confirmed endogenous CS patients in the U.S. who initiated osilodrostat treatment between May 1, 2020 and October 29, 2021.
- The study was approved by WIRB on October 29, 2021.
- U.S. sites with patients prescribed osilodrostat were approached to participate, a sub-set of sites agreed and entered patient data.
- Forty-two adult patients from 26 U.S. clinics with endogenous CS and a prescription for osilodrostat were included in this real-world study.
- We collected patients' medical history, laboratory results, concomitant medications, and signs and symptoms.
- We describe patients' experience with initial osilodrostat dose, dose titration, and persistence in the CD subset (n=34, 81%). (Table 1)

Table 1. Patient Characteristics

	CD Patients
Number of patients, n (%)	34 (81)
Age (years), mean, SD	40.8 (13.9)
Age at diagnosis (years), mean, SD	34.9 (12.7)
Female, n (%)	27 (79.4)
Race n (%)	
White	17 (50.0)
Black	8 (23.5)
Asian	1 (2.9)
More than one race	1 (2.9)
Unknown	7 (20.6)
Disease duration prior to osilodrostat, months, mean (SD)	57.3 (82.0)
Prior pituitary or adrenal surgery for CS, n (%)	32 (94.1)
Prior medical therapy for CS, n (%)	21 (61.8)


Table 2. Starting Doses in Cushing's Disease Patients

	Patients, n (%)
Total	34 (81)
1 mg QD	1 (2.9)
2 mg QD	1 (2.9)
1 mg BID	9 (26.5)
4 mg QD	1 (2.9)
2 mg BID	21 (61.8)
3 mg BID	1 (2.9)

Results

- In patients with CD (n=34), the mean total daily starting dose was 3.4 mg (SD 1.1; median 4 mg; range 1-6 mg/day).
- Starting doses varied (Table 2). 8 patients had a single encounter.
- In CD patients with multiple documented clinical encounters (n=26), mean days on therapy was 292.1 (median 298; range 15-547).
- 16 of 26 started at 4 mg/day
 - 4 patients (25%) had the dose interrupted or down-titrated within 71 days of treatment initiation; 2/4 of these patients experienced hypocortisolism-related symptoms and permanently discontinued
 - 5 patients (31%) were maintained on 4 mg/day throughout the observation period, with a mean (SD) treatment duration of 273 (median 278 days; SD 92) days
 - 7 patients (44%) had a dose up-titration; in 6/7 patients, initial dose increase was incremental (1-2 mg BID), and the mean (SD) time to up-titration was 78 (SD 25; median 83; range 40-108) days. (Figure 1)
- 10 of 26 started at <4 mg/day
 - 6 (60%) did not require dose reduction or interruption, all of which had up-titration in small increments (1-2 mg/day) and/or first titration at ≥80 days


Figure 1. Dose titrations in patients initiated on 4 mg/day with multiple clinical encounters



Osilodrostat Tolerance

- Osilodrostat was generally well tolerated.
- Symptoms related to decreased cortisol levels were reported in 10/26 patients (38%), including 3 patients with adrenal insufficiency based on physician characterization of patient symptoms and biochemistry and 7 patients with glucocorticoid withdrawal symptoms (e.g., dizziness, fatigue, headache, and nausea).

Figure 2. Osilodrostat dosing in representative patients during the study period



- Sample of patients showing various trends in response to osilodrostat treatment.
- Patient 1 was started on 2 mg BID with slow up-titration and had cortisol normalization with treatment persistence.
- Patient 2 was started on 2 mg BID with no up-titration and had cortisol normalization with treatment persistence.
- Patient 3 started at 1 mg QD with dose up-titration to 1 mg BID and had treatment persistence.
- Patient 4 was started on 1 mg BID with up-titration to 2 mg BID on D67. On D110 the dose was more than doubled which led to over-treatment; the patient subsequently experienced a rapid decrease in serum cortisol and required treatment interruption with ultimate discontinuation.

Conclusions

- ILLUSTRATE captures real-world U.S. data describing the experience of a subset of CD patients treated with osilodrostat.
- Of the 16 patients who started at 4 mg/day, 4 (25%) required interruption or down-titration and 5 (31%) remained on the initial dose throughout the observation period.
- One-third (11/34) of patients were started on lower than the indicated dose of 4 mg/day.
- Overall, patients with a gradual dose up-titration (i.e., prolonged titration interval) tended to have greater persistence with therapy.
- There were no new safety findings.

Limitations

- This chart review was limited by the small number of sites that participated.
- Patient abstractions were conducted by physicians via voluntary response sampling.
- Length of observation window during the index period varied across patients.
- Similar to other retrospective studies, this chart review was limited by what was documented in patient medical records, including labs, concomitant medications, and physician notes.